Target Name: DNAI2
NCBI ID: G64446
Other Name(s): dynein, axonemal, intermediate polypeptide 2 | Dynein intermediate chain 2 | Axonemal dynein intermediate chain 2 | Dynein axonemal intermediate chain 2 | dynein axonemal intermediate chain 2 | DNAI2_HUMAN | Dynein intermediate chain 2, axonemal | Dynein axonemal intermediate chain 2 (isoform 1) | Dynein axonemal intermediate chain 2, transcript variant 1 | CILD9 | DNAI2 variant 1 | DIC2

DNAI2 as A Potential Drug Target and Biomarker

DNAI2 (Dynaminein II) is a protein that is expressed in most tissues of the body, including muscle, nerve, and heart. It is a member of the dynein family of proteins, which are involved in the transport of organelles, including mitochondria and vesicles , in cells. DNAI2 is a cytoplasmic protein that is primarily localized to the endoplasmic reticulum (ER) and is involved in the transport of organelles to the cytoplasm.

Dynaminin II is a unique protein that is expressed in most tissues of the body and is involved in the transport of mitochondria to the cytoplasm. It is a 21-kDa protein that consists of 155 amino acids. It has a molecular weight of 191 kDa and a calculated pI of 9.5. DNAI2 is predominantly monomeric and has a single transmembrane domain.

DNAI2 is involved in the transport of mitochondria to the cytoplasm, where they are involved in energy metabolism. It is thought to play a role in the targeting of mitochondria to the cytoplasm and in the delivery of organelles, including the mitochondrial protein mitofusin, to the cytoplasm.

DNAI2 is a potential drug target and may be a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

Dynaminin II Interactions with other proteins

DNAI2 is a member of the dynein family of proteins, which are involved in the transport of organelles in cells. It interacts with several other proteins, including:

1. Dynein: DNAI2 is a subunit of the dynein complex, which is involved in the transport of mitochondria to the cytoplasm. It interacts with the cytoplasmic tail of dynein to form the cytoplasmic-endoplasmic transport vesicle.
2. Mitofusin: DNAI2 is involved in the delivery of mitochondrial protein mitofusin to the cytoplasm. It has been shown to interact with mitofusin and may play a role in the delivery of mitofusin to the cytoplasm.
3. Chaperone proteins: DNAI2 has been shown to interact with chaperone proteins, including HSP70 and HSP90. These proteins may play a role in the transport of DNAI2 and other proteins to the cytoplasm.
4. Adenylate cyclase: DNAI2 has been shown to interact with adenylate cyclase, which is involved in the regulation of cellular processes, including energy metabolism. This interaction may be involved in the delivery of organelles to the cytoplasm.

DNAI2 as a drug target

DNAI2 is a unique protein that is expressed in most tissues of the body and is involved in the transport of mitochondria to the cytoplasm. It is a potential drug target and may be a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the potential strategies for targeting DNAI2 is to use small molecules that can modulate its stability or activity. This can be done by binding to specific DNAI2 residues, such as the catalytic active site or the imidazole ring.

Another approach to targeting DNAI2 is to use antibodies that recognize specific DNAI2 epitopes. This can be done by using antibodies that recognize specific DNAI2 epitopes, such as the amino acid residues that are involved in the interaction with other proteins, such as dynein, mitofusin, and chaperone proteins.

DNAI2 as a biomarker

DNAI2 is a unique protein that is expressed in most tissues of the body and is involved in the transport of mitochondria to the cytoplasm. It may be a useful biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the potential uses of DNAI2 as a biomarker is its ability to be targeted to specific tissues and organs, such as cancer cells and neurodegenerative diseases. This can be done by using antibodies that recognize specific DNAI2 epitopes, such as the amino acid residues that are involved in the interaction with other proteins.

Another potential use of DNAI2 as a biomarker is its ability to be affected by certain diseases, such as cancer and neurodegenerative diseases. This can be done by using small molecules that can modulate

Protein Name: Dynein Axonemal Intermediate Chain 2

Functions: Part of the dynein complex of respiratory cilia

More Common Targets

DNAI3 | DNAI4 | DNAI7 | DNAJA1 | DNAJA1P3 | DNAJA1P4 | DNAJA1P5 | DNAJA2 | DNAJA3 | DNAJA4 | DNAJB1 | DNAJB11 | DNAJB12 | DNAJB13 | DNAJB14 | DNAJB2 | DNAJB3 | DNAJB4 | DNAJB5 | DNAJB6 | DNAJB6P1 | DNAJB7 | DNAJB8 | DNAJB8-AS1 | DNAJB9 | DNAJC1 | DNAJC10 | DNAJC11 | DNAJC12 | DNAJC13 | DNAJC14 | DNAJC15 | DNAJC16 | DNAJC17 | DNAJC17P1 | DNAJC18 | DNAJC19 | DNAJC2 | DNAJC21 | DNAJC22 | DNAJC24 | DNAJC25 | DNAJC25-GNG10 | DNAJC27 | DNAJC27-AS1 | DNAJC28 | DNAJC3 | DNAJC3-DT | DNAJC30 | DNAJC4 | DNAJC5 | DNAJC5B | DNAJC5G | DNAJC6 | DNAJC7 | DNAJC8 | DNAJC8P3 | DNAJC9 | DNAJC9-AS1 | DNAL1 | DNAL4 | DNALI1 | DNASE1 | DNASE1L1 | DNASE1L2 | DNASE1L3 | DNASE2 | DNASE2B | DND1 | DNER | DNHD1 | DNLZ | DNM1 | DNM1L | DNM1P33 | DNM1P35 | DNM1P41 | DNM1P46 | DNM1P49 | DNM2 | DNM3 | DNM3OS | DNMBP | DNMBP-AS1 | DNMT1 | DNMT1-G9a-PCNA complex | DNMT1-HDAC2-DMAP1 complex | DNMT1-Rb-E2F1-HDAC1 complex | DNMT3A | DNMT3AP1 | DNMT3B | DNMT3L | DNPEP | DNPH1 | DNTT | DNTTIP1 | DNTTIP2 | DOC2A | DOC2B | DOC2GP